June 2010
Worldwide Biotech;Jun2010, Vol. 22 Issue 6, p7
Trade Publication
The article reports on the final agreement signed by Bellus Health and Celtic Therapeutics for the development of the Phase III investigational product candidate KIACTA in the U.S. in June 2010. It says that Celtics Therapeutics will acquire the rights to KIACTA as well as the rights to license it worldwide, with upfront payments of 10 million U.S. dollars. According to the author, KIACTA is being developed to treat the life-threatening orphan disease called AA amyloidosis. The terms of the deal and its significance to both firms are also discussed.


Related Articles

  • Phase III Study Seeks to Boost Kiacta's Prospects. Powers, Marie // BioWorld Today;12/16/2010, Vol. 21 Issue 242, p1 

    The article reports on the confirmatory phase III study initiated by Bellus Health and its development partner Celtic Therapeutics LLP for amyloid A (AA) amyloidosis drug candidate Kiacta (eprodisate). The safety and efficacy of Kiacta in preventing renal function decline in patients with AA...

  • OTHER NEWS TO NOTE.  // BioWorld Today;4/30/2010, Vol. 21 Issue 83, p6 

    This section offers news briefs related to the pharmaceutical industry as of April 30, 2010. The AlphaRx Inc. and Pacific Orient Capital Inc. will merge in a stock transaction after signing a nonbiding letter of intent. Bellus Health entered a deal with Celtic Therapeutics for the latter's...

  • Bellus Health initiates Phase I Alzheimer's study.  // PharmaWatch: CNS;May2010, Vol. 9 Issue 5, p6 

    The article discusses the Phase I clinical study for the treatment of Alzheimer's disease that was initiated by Bellus Health Inc.

  • Financings roundup.  // Medical Device Daily;4/20/2009, Vol. 13 Issue 74, p3 

    The article reports on the completion of Bellus Health's first tranche of its previously reported Canadian $20.5 million fund. The company received gross proceeds for the issuance of new convertible notes. A second tranche from Vitus Investments III Private Limited is scheduled to be funded in...

  • Financings roundup.  // Medical Device Daily;7/9/2009, Vol. 13 Issue 130, p5 

    The article reports on a preliminary short form prospectus that will be filed by Bellus Health in each of the provinces of Canada for a 12,080,018 million Canadian dollars rights offering to holders of its common shares. The terms of the rights offering allow one right to be issued for each...

  • Financings Roundup.  // BioWorld Today;7/9/2009, Vol. 20 Issue 130, p5 

    The article reports on the filing by Bellus Health Inc. of a preliminary short-form prospectus in each of the Canadian provinces for the rights offering of about $12.08 million Canadian dollars to holders of its common shares. Eligible shareholders will be allowed to purchase one common share of...

  • Clinic Roundup.  // BioWorld Today;5/28/2013, Vol. 24 Issue 101, p5 

    The article reports on the feedback received by Adherex Technologies Inc. from the U.S. Food and Drug Administration (FDA) regarding its proposal to test eniluracil/5-FU/leucovorin in metastatic breast cancer patients and the announcement by Bellus Health Inc. that the data safety monitoring...

  • MED-TECH NEWS AND NOTES.  // Medical Device Daily;12/18/2008, Vol. 12 Issue 225, p5 

    The article reports on the preparation by Bellus Health to voluntary delist from the Nasdaq Capital Market, while continuing to maintain a full listing on the Toronto Stock Exchange in Toronto, Ontario. According to the article, the company received a letter from the Nasdaq Staff stating that...

  • BioWorld Stock Report For Public Biotechnology Companies.  // BioWorld Insight;8/26/2013, Vol. 21 Issue 35, p15 

    A table is presented related to stock report for public biotechnology companies as compiled by the periodical including Aastrom Biosciences Inc., Bellus Health Inc., and Chimerix Inc.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics